Extra Curricular Life Skills Training Manual For Adolescents 13 to 18 Years of Age
“Protecting Our Peers From HIV Infection”
The Youth Health and Development Programme Government of the Republic of Namibia and UNICEF Programme of Cooperation 1997-2001
November 1999
Vinay P. Saldanha( UNAIDS Regional Director- Eastern Europe & Central Asia)
Session 1 Wednesday 30/01/2019
30-31 January 2019, Bucharest
Accessed: 29.09.2019
Volumen 5 / Número 1 , 1025-1028 • http://www.revistabionatura.com
To describe the behavior of Tuberculosis/Human Immunodeficiency Virus co-infection in a cohort of people affected by sensitive Tuberculosis in Ecuador from 01 January 2010 to 31 December 2015. Results: The percentage of co...infected persons reached 11% in the whole period of study, with a range from 8.4% to 12.7%. Male sex shows the highest incidence rate, representing 76.7% at the rate of 1 man for every 3.3 women. The population with the highest incidence of patients is economically active; the age group of 25-34 years reaches 40.1%. The coastal zone of the country reports more than 75% of the coinfected patients. Conclusion: Increased HIV/AIDS screening should be increased for Tuberculosis, with particular emphasis on male sex and enhance the actions in the coastal provinces.
more
The development of this draft Proposed programme budget 2022–2023 comes at a unique moment for WHO. The world is in the grip of the coronavirus disease (COVID-19) pandemic and faces health, social and economic consequences on an unprecedented scale. Although it is not known when the COVID-19 pande...mic will end, recent encouraging vaccine results, in addition to the examples of countries that have achieved good results through public health measures, hold out the prospect of better days ahead. The full impact of the pandemic cannot yet be determined. But whatever its implications, the Secretariat will rise to the challenge and is ready to adapt so that it is fully equipped to support Member States for any eventuality in the future – to make sure that the world will never again have to face this kind of crisis.
more
Breakthrough innovations have come to light that have proved to be more than 95% effective in preventing HIV infection with injections just twice a year. Once a year might even be possible. They could also be key for 40 million people living with HIV around the world who need better options for trea...tment. It’s not a cure or a vaccine, but it could be a game-changer if made accessible to all who could benefit.
more
Page visited January 2019, publication date unknown.
Science / People / Progress
Accessed: 12.11.2019
No publication year indicated.
Will COVID-19 vaccines be safe? Will all the COVID-19 candidate vaccines be successful? What are the different phases a vaccine must go through to be approved? This document provides responses to the most frequently asked questions about candidate vaccines and access to COVID-19 vaccination.
Q3: For behavioural and psychological symptoms in people with dementia, do following drugs, when compared to placebo/comparator, produce benefits/harm in the specified outcomes?
Published: 5 January 2010 Received: 30 January 2009
BMC Neurology 2010, 10:1 doi:10.1186/1471-2377-10-1
This article is available from: http://www.biomedcentral.com/1471-2377/10/1
Malawi Internationally recommended key policies uptake
This report, published in conjunction with a summary overview of results of rounds 1–8, is the eighth and final report in a series of laboratory-based evaluations of rapid diagnostic tests (RDTs) for malaria. It provides a comparative measure of their performance in a standardized way to distingu...ish between well and poorly performing tests.
These results constitute the laboratory evaluation component of the WHO prequalification process for malaria RDTs and inform the current WHO procurement recommendations. In round 8, 35 RDTs from 17 manufacturers were assessed. For the first time the evaluation included an assessment of product performance against a panel of P. falciparum parasites with pfhrp2/3 gene deletions and therefore not expressing HRP2.
more
Document No. : FDA/SMC/SMD/GL-RAR/2013/01